SOAT1 and metabolic syndrome: The JAK-STAT signaling pathway, a critical regulator of various factors, when broadly inhibited, may contribute to vascular endothelial dysfunction, an imbalance in the coagulation-fibrinolysis system, and dyslipidemia, among other adverse effects.